For the Inventor, By the Inventor

Enter assignee name

Marburg, Germany

Behringwerke Aktiengesellschaft

USPTO Granted Patents = 340

% Expired Patents = 0.29

CIPO Patents = 5

Trademarks = 2

Forward Citations = 4,765

Loading Chart...

Loading Chart...

355 inventors (with patents filed for the assignee):

Norbert Heimburger (30 out of 38 patents)

Edwin F Ullman (27 out of 199 patents)

Hans Bohn (24 out of 25 patents)

4. Werner Stuber (20 out of 24 patents)

5. Klaus Bosslet (17 out of 37 patents)

6. Cenek Kolar (15 out of 23 patents)

7. Hans P Kraemer (11 out of 16 patents)

8. Peter Hermentin (10 out of 17 patents)

9. Gerhard Dickneite (9 out of 29 patents)

10. Dieter Hoffmann (9 out of 14 patents)

11. Gerhardt Kumpe (9 out of 14 patents)

12. Horst Schwinn (9 out of 16 patents)

13. Klaus Habenstein (9 out of 16 patents)

14. Hermann Erich Karges (9 out of 10 patents)

15. Gerhard Seemann (8 out of 19 patents)

Core Competencies:

Immunoassays

Nucleic Acid Amplification

Tumor-Selective Therapy

Monoclonal Antibodies

Glycoproteins

Peptides

Biosensors

Prodrugs

Genetic Selection

Cell Cultures

Fluorogenic Compounds

Antibodies

340 patents: Sort by Forward Citations

1. 8552159 - Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy (2013-10-08),

2. 7273727 - Fusion proteins for prodrug activation (2007-09-25),

3. 6294323 - Self initiating single primer amplification of nucleic acids (2001-09-25),

4. 6162631 - Retrovirus from the HIV group and its use (MVP-2901/94) (2000-12-19),

5. 6124090 - Nucleic acid amplification using single primer (2000-09-26),

6. 6090567 - Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases (2000-07-18),

7. 6020461 - Hexapeptides of Neisseria gonorrhoeae (2000-02-01),

8. 5985550 - Double receptor polynucleotide assay method (1999-11-16),

9. 5981697 - Synthetic peptides, antibodies against them and their use (1999-11-09),

10. 5981227 - Process for the production of proteins (1999-11-09),

11. 5955100 - Prodrugs their preparation and use as pharmaceuticals (1999-09-21),

12. 5939389 - Use of C1-inactivation for therapy of certain diseases (1999-08-17),

13. 5902740 - Process for the decontamination of cell cultures containing mycoplasmas (1999-05-11),

14. 5892144 - Biosensor (1999-04-06),

15. 5883256 - Process for removing aromatic heterocyclic compounds product-containing (1999-03-16),

Company Overview

Behringwerke Aktiengesellschaft, based in Marburg, Germany, specializes in the development and manufacturing of advanced immunoassays and nucleic acid amplification technologies. The company focuses on innovative solutions in tumor-selective therapy, utilizing monoclonal antibodies, glycoproteins, and peptides to enhance therapeutic efficacy. Additionally, Behringwerke is engaged in the creation of biosensors and prodrugs, contributing to the advancement of precision medicine and diagnostics in the healthcare sector.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

340 Patents

#1 in Marburg

#172 in Germany

#2,669 in the World

Marburg, Germany

Behringwerke Aktiengesellschaft

Forward Citations = 4,765

355 inventors:

Norbert Heimburger (30 out of 38 patents)

Edwin F Ullman (27 out of 199 patents)

Hans Bohn (24 out of 25 patents)

4. Werner Stuber (20 out of 24 patents)

5. Klaus Bosslet (17 out of 37 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Behringwerke Aktiengesellschaft. Retrieved from https://idiyas.com/company/behringwerke-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…